Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

Supplerende målrettet temperaturstyring ved akut alvorlig kulilteforgiftning

8. november 2026 opdateret af: Yong Sung Cha, Wonju Severance Christian Hospital

Målrettet temperaturstyring kombineret med hyperbar iltterapi ved akut alvorlig kulilteforgiftning: Multicenter randomiseret kontrolleret klinisk forsøg (TTM-COHB-forsøg)

This randomized trial will investigate important neurocognitive clinical outcomes of patients with acute severe carbon monoxide poisoning (ASCOP) randomized to receive either therapeutic hypothermia or normothermia combined with hyperbaric oxygen therapy (HBO).

Studieoversigt

Status

Afsluttet

Betingelser

Intervention / Behandling

Detaljeret beskrivelse

CO-poisoned patients are identified by medical history and carboxyhemoglobin (CO-Hb) value >5% (>10% in smokers). Patients presenting with acute CO poisoning will receive one HBO. ASCOP is defined as mental status showing response to painful stimulus or unresponsiveness requiring intubation for airway protection and ventilation support at the emerency department, and persistence of depressed mental status despite the HBO. After HBO treatment, eligible patients who provide consent will be randomly allocated to receive hypothermia, or normothermia treatment administered in a open label fashion except for blinding of outcome assessor.

Outcome measures will be administered at 1 month and 6 months after CO exposure. In addition, we will examine the differences in serum markers and mortality between the hypothermia and normothermia groups.

Undersøgelsestype

Interventionel

Tilmelding (Faktiske)

39

Fase

  • Ikke anvendelig

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiesteder

    • Gangwon-do
      • Wŏnju, Gangwon-do, Sydkorea, 26426
        • Wonju Severance Christian Hospital
    • Incheon
      • Incheon, Incheon, Sydkorea, 22332
        • Inha University Hospital

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

19 år og ældre (Voksen, Ældre voksen)

Tager imod sunde frivillige

Ingen

Køn, der er berettiget til at studere

Alle

Beskrivelse

Inclusion Criteria:

  • ≥ 19 years.
  • Patients who received HBO within 24 hours for acute CO poisoning.
  • Patients who meet the definition of ASCOP (Patients incapable verbal obey after HBO).
  • Signed informed consent prior to study entry.

Exclusion Criteria:

  • Cardiac arrest before HBO
  • Previous neurocognitive disorders
  • Life-threatening underlying disease (ex: advanced cancer)
  • Evidence of co-ingestion of sedative or hypnotics confirmed by intravenous flumazenil administration or history taking at the emergency department
  • Absolute contraindication for TH (active severe bleeding and profound shock not controlled by vasoactive drugs)
  • No admission
  • The significant co-ingested drug levels, which are alter the consciousness, is confirmed from the drug analysis lab
  • Pregnancy
  • Burns
  • More than moderate burn or Inhalation burn
  • Burns complicated by other trauma
  • Electrical burn
  • Burns in high risk patients (Patients with chronic underlying diseases (i.e DM, ESRD, liver cirrhosis, etc) which may cause delays or aggravate the wound healing)

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Behandling
  • Tildeling: Randomiseret
  • Interventionel model: Parallel tildeling
  • Maskning: Enkelt

Våben og indgreb

Deltagergruppe / Arm
Intervention / Behandling
Eksperimentel: Hypothermia group

Hypothermia group is then performed at a body temperature of 33±0.5 °C during 24 h using a surface cooling device as soon as possible after the HBO and research consent. After therapeutic hypothermia ended, rewarming is done slowly between 0.2℃ - 0.5℃/h for 12 hours. After rewarming, it will be held at 36.5 ℃ for 36 hours.

Targeted therapeutic hypothermia is then performed at a body temperature of 33±0.5 °C during 24 h using a surface cooling device as soon as possible after the HBO and research consent. After TH ended, rewarming is done slowly between 0.2℃ - 0.5℃/h for 12 hours. After rewarming, it will be held at 36.5 ℃ for 36 hours.

Aktiv komparator: Normothermia group

For normothermia group, it will be held at 36.5±0.5 ℃ for 72 hours using a surface cooling device after the HBO and research consent.

Targeted therapeutic normothermia will be held at 36.5±0.5 ℃ for 72 hours using a surface cooling device after the HBO and research consent.

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Main neurocognitive outcome
Tidsramme: At 6 months after CO poisoning

Global Deterioration Scale [range 1 - 7 (worst score)]

At 6 months after CO poisoning

Sekundære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Neurocognitive outcome
Tidsramme: At 1 month after CO poisoning

Global Deterioration Scale [range 1 - 7 (worst score)]

At 1 month after CO poisoning
Cerebral Performance Category
Tidsramme: At 1 month and 6 months after CO poisoning

Cerebral Performance Category [range 1 - 5 (worst score)]

At 1 month and 6 months after CO poisoning
modified Rankin scale
Tidsramme: At 1 month and 6 months after CO poisoning

modified Rankin scale [range 0 - 6 (worst score)]

At 1 month and 6 months after CO poisoning
Glasgow outcome scale
Tidsramme: At 1 month and 6 months after CO poisoning

Glasgow outcome scale [range 1 (worst score) - 5]

At 1 month and 6 months after CO poisoning
mini-mental status exam
Tidsramme: At 1 month and 6 months after CO poisoning

mini-mental status exam

At 1 month and 6 months after CO poisoning
Korean version of the Modified Barthel Index
Tidsramme: At 1 month and 6 months after CO poisoning

Korean version of the Modified Barthel Index

At 1 month and 6 months after CO poisoning
Mortality in intensive care unit
Tidsramme: Through study completion, an average of 6 months

Number of participants with mortality in intensive care unit

Through study completion, an average of 6 months
Mortality in intensive care unit
Tidsramme: Through study completion, an average of 6 months

Rate of participants with mortality in intensive care unit

Through study completion, an average of 6 months
In-hospital mortality
Tidsramme: Through study completion, an average of 6 months

Number of participants with in-hospital mortality

Through study completion, an average of 6 months
In-hospital mortality
Tidsramme: Through study completion, an average of 6 months

Rate of participants with in-hospital mortality

Through study completion, an average of 6 months
Mortality
Tidsramme: At 1, 3, and 6 months after CO poisoning

Number of participants with all cause mortality

At 1, 3, and 6 months after CO poisoning
Mortality
Tidsramme: At 1, 3, and 6 months after CO poisoning

Rate of participants with all cause mortality

At 1, 3, and 6 months after CO poisoning
Length of stay in intensive care unit and hospital
Tidsramme: Through study completion, an average of 6 months

Length of stay in intensive care unit and hospital

Through study completion, an average of 6 months
Pneumonia
Tidsramme: During the intervention (therapeutic hypothermia or normothermia) period (72 hours)

Number of participants with the diagnosis of pneumonia. Diagnosis is established when the following two criteria are met: 1) the appearance of a new infiltrate or consolidation on chest x-ray; and 2) leukocytosis, or leukopenia, or the significant presence of meaningful bacteria in a sputum culture with the absence of other infections.

During the intervention (therapeutic hypothermia or normothermia) period (72 hours)
Pneumonia
Tidsramme: During the intervention (therapeutic hypothermia or normothermia) period (72 hours)

Rate of participants with the diagnosis of pneumonia. Diagnosis is established when the following two criteria are met: 1) the appearance of a new infiltrate or consolidation on chest x-ray; and 2) leukocytosis, or leukopenia, or the significant presence of meaningful bacteria in a sputum culture with the absence of other infections.

During the intervention (therapeutic hypothermia or normothermia) period (72 hours)
Shock
Tidsramme: During the intervention (therapeutic hypothermia or normothermia) period (72 hours)

Number of participants with shock. Diagnosis is diagnosed when a vasopressor is needed to resuscitate the patient and lactate levels exceeded 2.0 mmol/L.

During the intervention (therapeutic hypothermia or normothermia) period (72 hours)
Shock
Tidsramme: During the intervention (therapeutic hypothermia or normothermia) period (72 hours)

Rate of participants with shock. Diagnosis is diagnosed when a vasopressor is needed to resuscitate the patient and lactate levels exceeded 2.0 mmol/L.

During the intervention (therapeutic hypothermia or normothermia) period (72 hours)
Bradycardia
Tidsramme: During the intervention (therapeutic hypothermia or normothermia) period (72 hours)

Number of participants with dropped heart rate indicated drug or interventions

During the intervention (therapeutic hypothermia or normothermia) period (72 hours)
Bradycardia
Tidsramme: During the intervention (therapeutic hypothermia or normothermia) period (72 hours)

Rate of participants with dropped heart rate indicated drug or interventions

During the intervention (therapeutic hypothermia or normothermia) period (72 hours)
Hypokalemia
Tidsramme: During the intervention (therapeutic hypothermia or normothermia) period (72 hours)

Number of participants with serum K concentration <3.0 - 2.5 mmol/L

During the intervention (therapeutic hypothermia or normothermia) period (72 hours)
Hypokalemia
Tidsramme: During the intervention (therapeutic hypothermia or normothermia) period (72 hours)

Rate of participants with serum K concentration <3.0 - 2.5 mmol/L

During the intervention (therapeutic hypothermia or normothermia) period (72 hours)
Hyperkalemia
Tidsramme: During the intervention (therapeutic hypothermia or normothermia) period (72 hours)

Number of participants with serum K concentration >6.0 - 7.0 mmol/L

During the intervention (therapeutic hypothermia or normothermia) period (72 hours)
Hyperkalemia
Tidsramme: During the intervention (therapeutic hypothermia or normothermia) period (72 hours)

Rate of participants with serum K concentration >6.0 - 7.0 mmol/L

During the intervention (therapeutic hypothermia or normothermia) period (72 hours)
Hyperglycemia
Tidsramme: During the intervention (therapeutic hypothermia or normothermia) period (72 hours)

Number of participants with change (Insulin therapy initiated) in daily management from baseline for serum glucose

During the intervention (therapeutic hypothermia or normothermia) period (72 hours)
Hyperglycemia
Tidsramme: During the intervention (therapeutic hypothermia or normothermia) period (72 hours)

Rate of participants with change (Insulin therapy initiated) in daily management from baseline for serum glucose

During the intervention (therapeutic hypothermia or normothermia) period (72 hours)
Hypophosphatemia
Tidsramme: During the intervention (therapeutic hypothermia or normothermia) period (72 hours)

Number of participants with a disorder characterized by laboratory test results that indicate a low concentration of phosphates in the blood and indicated replacement therapy

During the intervention (therapeutic hypothermia or normothermia) period (72 hours)
Hypophosphatemia
Tidsramme: During the intervention (therapeutic hypothermia or normothermia) period (72 hours)

Rate of participants with a disorder characterized by laboratory test results that indicate a low concentration of phosphates in the blood and indicated replacement therapy

During the intervention (therapeutic hypothermia or normothermia) period (72 hours)
Hypomagnesemia
Tidsramme: During the intervention (therapeutic hypothermia or normothermia) period (72 hours)

Number of participants with serum magnesium <0.9 - 0.7 mg/dL

During the intervention (therapeutic hypothermia or normothermia) period (72 hours)
Hypomagnesemia
Tidsramme: During the intervention (therapeutic hypothermia or normothermia) period (72 hours)

Rate of participants with serum magnesium <0.9 - 0.7 mg/dL

During the intervention (therapeutic hypothermia or normothermia) period (72 hours)
Prolonged prothrombin Time International Normalized Ratio
Tidsramme: During the intervention (therapeutic hypothermia or normothermia) period (72 hours)

Number of participants with >2.5 x upper limit of the normal range and bleeding

During the intervention (therapeutic hypothermia or normothermia) period (72 hours)
Prolonged prothrombin Time International Normalized Ratio
Tidsramme: During the intervention (therapeutic hypothermia or normothermia) period (72 hours)

Rate of participants with >2.5 x upper limit of the normal range and bleeding

During the intervention (therapeutic hypothermia or normothermia) period (72 hours)
Prolonged activated partial thromboplastin time
Tidsramme: During the intervention (therapeutic hypothermia or normothermia) period (72 hours)

Number of participants with >2.5 x upper limit of the normal range and bleeding

During the intervention (therapeutic hypothermia or normothermia) period (72 hours)
Prolonged activated partial thromboplastin time
Tidsramme: During the intervention (therapeutic hypothermia or normothermia) period (72 hours)

Rate of participants with >2.5 x upper limit of the normal range and bleeding

During the intervention (therapeutic hypothermia or normothermia) period (72 hours)
S100ß (serum)
Tidsramme: Within 14 days after CO exposure

Concentration of S100ß (serum)

Within 14 days after CO exposure
Neuronal specific enolase (serum)
Tidsramme: Within 14 days after CO exposure

Concentration of neuronal specific enolase (serum)

Within 14 days after CO exposure
Brain magnetic resonance image (MRI)
Tidsramme: Within 14 days after CO exposure

Number of participants with brain injury in brain MRI

Within 14 days after CO exposure
Brain magnetic resonance image (MRI)
Tidsramme: Within 14 days after CO exposure

Rate of participants with brain injury in brain MRI

Within 14 days after CO exposure

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Sponsor

Samarbejdspartnere

Efterforskere

  • Ledende efterforsker: Yong Sung Cha, MD, Wonju Severance Christian Hospital

Publikationer og nyttige links

Den person, der er ansvarlig for at indtaste oplysninger om undersøgelsen, leverer frivilligt disse publikationer. Disse kan handle om alt relateret til undersøgelsen.

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Faktiske)

25. oktober 2021

Primær færdiggørelse (Faktiske)

7. november 2025

Studieafslutning (Faktiske)

7. november 2025

Datoer for studieregistrering

Først indsendt

1. juli 2021

Først indsendt, der opfyldte QC-kriterier

13. juli 2021

Først opslået (Faktiske)

26. juli 2021

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

12. november 2026

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

8. november 2026

Sidst verificeret

1. juni 2025

Mere information

Begreber relateret til denne undersøgelse

Andre undersøgelses-id-numre

  • TTM-COHB trial
  • CR220011 (Anden identifikator: Wonju Severance Christian Hospital)
  • 2021-04-043 (Anden identifikator: Inha University Hospital)

Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter

Studerer et amerikansk FDA-reguleret lægemiddelprodukt

Ingen

Studerer et amerikansk FDA-reguleret enhedsprodukt

Ingen

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .